IDEAYA Biosciences, Inc. IDYA IDE034 — External Clinical Development Expenses

Similar metrics at other companies

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

BEAMExternal Research And Development Expenses — Research And Development Expense

$30.08M-12.6%

DNLITherapeutics Segment — External research and development expense

$38.46M-8.4%

INVAExternal Services — Research And Development Expense

$2.61M-14.6%

IRONDISC Three Four Zero Five — Research And Development Expense

$9.19M+451%

INSMOther external R&D expenses — R&D

$32.68M+16.4%

Questions, answered.

What is IDEAYA Biosciences, Inc.'s IDE034 — external clinical development expenses?

IDEAYA Biosciences, Inc. (IDYA) reported IDE034 — external clinical development expenses of $6.81M in Q1 2026.

What does IDE034 — external clinical development expenses mean?

This metric represents the direct costs incurred by the company for third-party services, clinical trial sites, and contract research organizations specifically associated with the clinical advancement of the IDE034 program. It captures the external capital intensity required to move this specific therapeutic candidate through human clinical trials and regulatory milestones. Monitoring this expense provides insight into the company's resource allocation strategy and the pace of development for this particular precision medicine asset.